- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06376643
Augmented Reality to Support Cardiopulmonary Resuscitation
Evaluation of an Augmented Reality and Screen-based Decision Support System for Cardiopulmonary Arrest: a Multicenter, Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Each year, thousands of children experience cardiopulmonary arrests (CA), requiring immediate and accurate resuscitation for favorable outcomes. However, adherence to American Heart Association (AHA) advanced life support guidelines remains suboptimal, hindered by cognitive and communication challenges in high-stress cardiopulmonary resuscitation (CPR) situations. To address this problem, will assess a novel augmented reality (AR)-assisted digital health solution designed to offer personalized, real-time decision support for team leaders and medication nurses, while concurrently optimizing team situational awareness and communication by projecting a dynamic care roadmap onto a large screen in the resuscitation room, controlled via a mobile tablet app.
The solution comprises three essential digitally interconnected elements: 1) a mobile app that presents clinical algorithms alongside patient data, guiding the resuscitation team through step-by-step procedures, 2) a giant screen that displays real-time patient information and task progress for the entire resuscitation team, and 3) augmented reality devices worn by team members, providing role-specific guidance and decision support based on data collected by the app.
In this trial, we will assess, amongst pediatric healthcare teams, whether the use of the AR-assisted tool improves adherence to AHA resuscitation guidelines and performance, while reducing medication errors, when compared to groups using the AHA pocket reference card (control) in an open-label, prospective, multicenter, cluster randomized (1:1 ratio) clinical trial. Sixty physicians and nurses will be recruited to form teams of 7, each managing simulated pediatric in-hospital cardiac arrest (IHCA) scenarios using either an AR-assisted tool or conventional AHA pocket reference cards. Each team will comprise three participants assigned to the roles of 1) Team Leader (a physician), 2) Charting Nurse, and 3) Medication Nurse, with two CPR Providers, an Airway Provider, and a Bedside Provider roles filled by research actors. All participants and actors will view a CPR Coach orientation video to ensure understanding of the CPR Coach and Provider functions
The primary outcome is the time in seconds to first dose of epinephrine. Secondary outcomes are times to CPR initiation, defibrillation, drug delivery, airway securing, the rate of medication errors, CPR pause frequency, CPR quality (excellent CPR percentage, chest compression fraction, peri-shock pause duration), provider workload (NASA-TLX survey) and stress (STAI), user experience (UEQ), system usability (SUS), and technology acceptance (UTAUT).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, AB T3B 6A8,
- Alberta Children's Hospital
-
-
-
-
-
Geneva, Switzerland, 1205
- Geneva Children's Hospital, Geneva University Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Inclusion criteria for the team leader include: attending physician, fellow, or senior resident in emergency medicine, pediatric emergency medicine, pediatrics, pediatric critical care, or pediatric anesthesia.
- Inclusion criteria for the medication and charting nurse roles include: nurse in pediatric emergency medicine, general pediatrics, or other pediatric acute care specialty.
- Inclusion criteria for all other team members include: pediatric attending physician, resident, fellow, nurse or respiratory therapist.
- Participants must have prior basic life support training.
- Participation agreement.
Exclusion Criteria:
- Decline to provide informed consent
- Previously enrolled
- Unable to perform tasks required of the role
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm A (Augmented Reality)
Participants that will use the augmented reality supportive tool during the simulation-based pediatric scenario.
|
Participants will view a standardized orientation video describing the clinical environment, equipment, manikin functionality, and participant roles, followed by a 15-minute table-top practice simulation where participants have opportunity to use the assigned intervention by running through a cardiac arrest scenario. Then, participants will undertake a 20-minute tightly standardized cardiac arrest simulation scenario using a high-fidelity pediatric manikin. The scenarios will be videotaped from a bird's-eye view angle at the foot of the bed, along with three action video cameras worn by the participants, and positioned within the room. Following completion of the scenario, participants will fill out five surveys (see secondary outcomes), which together take about 15 minutes to fill. |
|
Active Comparator: Arm B (Conventional methods)
Participants that will use conventional methods during the simulation-based pediatric scenario.
|
Participants will view a standardized orientation video describing the clinical environment, equipment, manikin functionality, and participant roles, followed by a 15-minute table-top practice simulation where participants have opportunity to use the assigned intervention by running through a cardiac arrest scenario Then, participants will undertake a 20-minute tightly standardized cardiac arrest simulation scenario using a high-fidelity pediatric manikin. The scenarios will be videotaped from a bird's-eye view angle at the foot of the bed, along with three action video cameras worn by the participants, and positioned within the room. Following completion of the scenario, participants will fill out five surveys (see secondary outcomes), which together take about 15 minutes to fill. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to first dose of epinephrine
Time Frame: 20 minutes
|
The primary outcome is the time in seconds to first dose of epinephrine administration
|
20 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to initiation of cardiopulmonary resuscitation
Time Frame: 20 minutes
|
The time in seconds from the investigator's clinical statement to initiation of chest compression
|
20 minutes
|
|
Time to defibrillation
Time Frame: 20 minutes
|
The time in seconds from the investigator's clinical statement to each manual defibrillator shock delivery
|
20 minutes
|
|
Time to delivery of epinephrine
Time Frame: 20 minutes
|
The time in seconds from the investigator's clinical statement to intravenous injection of epinephrine to treat underlying condition
|
20 minutes
|
|
Time to delivery of amiodarone
Time Frame: 20 minutes
|
The time in seconds from the investigator's clinical statement to intravenous injection of amiodarone to treat underlying condition
|
20 minutes
|
|
Time to secure definitive airway
Time Frame: 20 minutes
|
The time in seconds from the investigator's clinical statement to the successful establishment of a definitive airway via endotracheal intubation
|
20 minutes
|
|
Medication dosage errors
Time Frame: 20 minutes
|
Errors in drug dose administration (milligrams), defined as a deviation from the correct weight-based dose of more than 10% according to predefined, expert consensus-based criteria, will be measured (i.e., absolute and percentage deviation) in each allocation group as a deviation from the 2020 AHA Pediatric Advanced Life Support cardiac arrest algorithm.
|
20 minutes
|
|
Types of Medication Errors
Time Frame: 20 minutes
|
The nature of the error type will be recorded, such as incorrect drug selection (i.e., administering the wrong medication), administration timing errors (i.e., administering the medication at the wrong time during the resuscitation process), labeling errors (i.e., misinterpreting or misreading the medication label), equipment-related errors (i.e., issues related to the functioning or availability of equipment needed for drug administration [e.g., syringe malfunction]), and documentation errors (i.e., inaccurate or incomplete recording of medication administration details)
|
20 minutes
|
|
Frequency of Medication Errors
Time Frame: 20 minutes
|
Number of times medication errors occur during the cardiac arrest scenario
|
20 minutes
|
|
Frequency of pauses in cardiopulmonary resuscitation
Time Frame: 20 minutes
|
Number of times of cardiopulmonary resuscitation pauses during the cardiac arrest scenario
|
20 minutes
|
|
Duration of pauses in cardiopulmonary resuscitation
Time Frame: 20 minutes
|
The total time in seconds of cardiopulmonary resuscitation pauses during the cardiac arrest scenario
|
20 minutes
|
|
Causes of pauses in cardiopulmonary resuscitation
Time Frame: 20 minutes
|
The causes leading to resuscitation interruptions will be identified and documented
|
20 minutes
|
|
Cardiopulmonary resuscitation quality: Percentage of overall excellent cardiopulmonary resuscitation
Time Frame: 20 minutes
|
The proportion of cardiopulmonary resuscitation administrations that meet the predefined AHA standards for high-quality resuscitation techniques.
|
20 minutes
|
|
Cardiopulmonary resuscitation quality: Chest compression fraction
Time Frame: 20 minutes
|
The fraction of time in seconds that chest compressions are being performed over the total cardiopulmonary resuscitation duration
|
20 minutes
|
|
Cardiopulmonary resuscitation quality: Peri-shock pause duration
Time Frame: 20 minutes
|
The length of time in seconds between the cessation of chest compressions and the delivery of a defibrillation shock during cardiopulmonary resuscitation
|
20 minutes
|
|
Provider workload (NASA-TLX)
Time Frame: 15 minutes
|
Assessed via NASA-TLX.
It measures mental burden across 6 dimensions: mental, physical, temporal demands, performance, effort, and frustration.
Scores range from 0 to 100 in 5-point increments (0: no task load; 100: maximal task load).
Participants rate each dimension based on their perceived workload.
To combine the dimensions into a final score, a weighting procedure is used.
This involves comparing each dimension with every other dimension to determine its relative importance in influencing workload.
Participants select the dimension that contributes most to workload in each pair of comparisons.
Each dimension is then weighted based on the participant's selections, with higher weights given to dimensions that are chosen more frequently.
The weighted scores for each dimension are summed to calculate the overall score, which ranges from 0 (minimal task load) to 100 (maximal task load)
|
15 minutes
|
|
User Experience Questionnaire (UEQ)
Time Frame: 15 minutes
|
UEQ is a widely used questionnaire to measure the subjective impression of users towards the user experience of products.
The UEQ is a semantic differential with 26 items that are grouped into six scales (Attractiveness, Perspicuity, Efficiency, Dependability, Stimulation, and Novelty).
Each scale represents a distinct usability quality aspect.
The minimum value is 0 (i.e., the worst user experience) and the maximum value is 100 (i.e., the best user experience).
Participants will be asked to complete the UEQ directly after they have completed the resuscitation scenario
|
15 minutes
|
|
System Usability Scale (SUS)
Time Frame: 15 minutes
|
SUS is a widely used questionnaire for assessing the perceived usability of a system or product.
The SUS consists of a 10-item questionnaire where users rate their agreement or disagreement with a series of statements regarding the usability of a system using a 5-point Likert scale (1 to 5).
The minimum value is 0 (i.e., the system is not usable) and the maximum value is 100 (i.e., the system is absolutely usable).
Participants will be asked to complete the SUS directly after they have completed the resuscitation scenario
|
15 minutes
|
|
Unified Theory of Acceptance and Use of Technology questionnaire (UTAUT)
Time Frame: 15 minutes
|
The UTAUT consists of eight domains (performance expectancy, effort expectancy, social influence, facilitating conditions, hedonic motivation, price value, habit, and behavioural intention).
This measure will be adapted to assess participants' perceived usability, usefulness, and intention to use the augmented reality-aided tool after study completion.
Responses are rated on a 7-point likert scale from 1=Strongly disagree to 7=Strongly agree.
Participants will be asked to complete the UTAUT directly after they have completed the resuscitation scenario
|
15 minutes
|
|
State-Trait Anxiety Inventory (STAI) form Y-1
Time Frame: 15 minutes
|
This questionnaire is composed of 20-item self-report subscales to measure the temporary state of anxiety at the time of reporting (STAI form Y-1), which can be affected by stressful situations.
Each item is answered on a 4-point Likert scale ranging from 1 (not at all) to 4 (very much).
After reversing the scores for stress-absent items (ie, items 1, 2, 5, 8, 10, 11, 15, 16, 19, and 20), the total score is calculated by summing up the weighted scores for the 20 items.
STAI ranges from 20 to 80, with higher scores being positively correlated with greater stress.
The range of possible scores range from a minimum score of 20 to a maximum score of 80. STAI scores are commonly classified as "no or low anxiety" (20-37), "moderate anxiety" (38-44), and "high anxiety" (45-80).
Participants will be asked to complete the STAI directly after they have completed the resuscitation scenario
|
15 minutes
|
|
Visual attention patterns of team leader and medication nurse on augmented reality and resuscitation room elements
Time Frame: 20 minutes
|
Duration and number of visual fixations on pre-defined area of interest (AOI) for the team leader and medication nurse, as captured by the augmented reality device (Microsoft Hololens2).
AOIs will include the holograms projected within each augmented reality device, as well as the LCD screen within the resuscitation room and manikin for the team leader.
|
20 minutes
|
|
Team Emergency Assessment Measure (TEAM) survey
Time Frame: 10 minutes
|
The TEAM survey is a validated tool designed to assess team performance during emergency scenarios, focusing on non-technical skills.
It consists of 11 items rated on a 5-point Likert scale (0 [Never/Hardly ever] to 4 [Always/Nearly always]) across three domains: Leadership, Teamwork, and Task Management, with an additional overall performance rating.
Scores range from 0 (poor performance) to 44 (excellent performance), providing a comprehensive measure of team dynamics, communication, and coordination.
Participants will complete the TEAM survey immediately after each resuscitation scenario to evaluate the team's effectiveness in managing the simulated IHCA
|
10 minutes
|
|
Concise Assessment of Leader Management (CALM) Survey
Time Frame: 10
|
The CALM survey is a validated tool for assessing leadership in acute resuscitation scenarios, focusing on the Team Leader's performance.
It includes 15 four-point Likert scale items (rarely, sometimes, mostly, always) across 4 domains-Leadership (role and style, 2 items), Communication (clarity and closed-loop reinforcement, 2 items), Team Management (role assignment, task direction, workload balance, team engagement, and case summarization, 5 items), and Medical Management (task prioritization, global awareness, patient reassessment, care planning, and help-seeking, 5 items)-plus 1 dichotomous behavioral item (yes/no on role announcement) and 1 global rating item comparing the leader to peers (below expected, as expected, above expected, top 5%).
Scores for the Likert items range from 15 (poor leadership) to 60 (outstanding leadership), with additional binary and comparative assessments.
Team members will complete the CALM survey immediately after each resuscitation scenario.
|
10
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Johan N Siebert, MD, PD, Geneva Children's Hospital, Geneva, Switzerland
- Study Director: Adam Cheng, Prof, Alberta Children's Hospital, Calgary, Canada
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- InterFACE-AR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation in ChildrenCompletedPediatric Heart Transplantation | Pediatric Heart Transplant Recipients | Pediatric Cardiac TransplantationUnited States
-
Istanbul University - CerrahpasaNot yet recruitingPediatric Anesthesia | Pediatric Postoperative Recovery | Pediatric Enhanced Recovery After SurgeryTurkey (Türkiye)
-
Muhammed Ata Nur GEÇERBakirkoy Dr. Sadi Konuk Research and Training HospitalNot yet recruitingPediatric | Pediatric Acute Upper Respiratory Tract Infection | Pediatric Acute Respiratory Failure
-
Akdeniz UniversityNot yet recruitingPediatric Oncology | Pediatric Hematology
-
Samsung Medical CenterMinistry of Health, Republic of KoreaRecruitingRelapsed Pediatric AML | Refractory Pediatric AML | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
-
University Hospital, Strasbourg, FranceTerminatedPediatric Lung Ultrasound | Pediatric Chest Radiography | Pediatric Lung DiagnosisFrance
-
University of BirminghamCompletedCancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AMLUnited Kingdom, Australia, Netherlands
-
Duke UniversityRecruiting
-
Alexandria UniversityNot yet recruitingPediatric Dental Anxiety | Pediatric Dental PainEgypt
-
Gødstrup HospitalAarhus University HospitalRecruitingPediatric Anesthesia | PROMs | Pediatric Surgery | PREMsDenmark
Clinical Trials on Augmented reality supportive tool
-
H. Lee Moffitt Cancer Center and Research InstituteNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Completed
-
New York UniversityCompletedHIV TestingUnited States
-
Vanderbilt University Medical CenterVanderbilt University; National Institute for Biomedical Imaging and Bioengineering...Completed
-
Chinese University of Hong KongCompleted
-
Vanderbilt University Medical CenterVanderbilt University; National Institute for Biomedical Imaging and Bioengineering...Recruiting
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUniversity of BolognaRecruiting
-
Brigham and Women's HospitalWithdrawnPain | Infection | MalignancyUnited States
-
University of PittsburghNortheastern University; NSFRecruiting
-
Vanderbilt University Medical CenterVanderbilt University; National Institute for Biomedical Imaging and Bioengineering...Completed
-
Koç UniversityKoç University HospitalCompleted